Status:
COMPLETED
Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Conditions:
Obsessive Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacologica...
Detailed Description
Arm 1: SSRI (Fluoxetine 40mg\* once a day) + Clomipramine 75mg\* once a day. Arm 2: SSRI (Fluoxetine 40mg\* once a day) + Quetiapine 200mg\* once a day. Arm 3: SSRI (Fluoxetine 80mg\* once a day) + ...
Eligibility Criteria
Inclusion
- OCD diagnosis
- YBOCS score ≥ 16 (for patients with both obsessions and compulsions) or ≥ 10 (for patients with only obsessions or compulsions)
- Previously signed informed consent to participate in this clinical trial
Exclusion
- Patients with clinical or neurological diseases that may be worsen by the medications included in treatment protocol
- Current substance dependence or abuse
- Current psychotic symptoms
- Current suicide risk
- Current pregnancy or intention to get pregnant before the end of the treatment protocol
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00466609
Start Date
May 1 2007
End Date
April 1 2010
Last Update
October 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Psychiatry
São Paulo, São Paulo, Brazil, 05403-010